A new system for delivering cancer drugs directly to the brain
Official title: Smart CSF Delivery System for CNS Drug Therapy for Leptomeningeal Disease
Funded at Enclear Therapies, INC. · NIH-10819360 · Data updated 2026-11-12
This study is working on a new way to deliver chemotherapy directly into the fluid around the brain for patients with brain cancer, aiming to make the treatment more effective than the usual methods.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Enclear Therapies, INC. NIH-funded |
| Lab location | 1 site (Newburyport, UNITED STATES) |
| Project start | July 1, 2024 |
| Project end | December 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $295,851 |
| NIH project number | 1R43CA281429-01A1 |
| Project ID | NIH-10819360 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with leptomeningeal disease or brain tumors who require chemotherapy treatment.
✕Less likely to help
Patients with conditions not involving the central nervous system or those who are not candidates for chemotherapy may not benefit from this research.
What this research studies
This research focuses on developing a smart delivery system that enhances the administration of chemotherapy drugs directly into the cerebrospinal fluid (CSF) for patients with brain cancer. By using a specialized platform, the study aims to improve the distribution and penetration of drugs like Topotecan, which are often ineffective when delivered through traditional intravenous methods due to the blood-brain barrier. The project will involve testing this delivery system in a large animal model to ensure its safety and effectiveness before considering human trials.
Why it matters
Potential benefit: If successful, this research could significantly improve treatment outcomes for patients with brain tumors by ensuring more effective drug delivery directly to affected areas.
How similar studies have gone: While the approach of enhancing drug delivery to the brain is being explored, this specific method of using a smart CSF delivery system is novel and has not been extensively tested in prior studies.
Where this research is happening
-
Enclear Therapies, INC.
Newburyport, United States Active
Researchers
- Principal investigator: Glicksman, Marcie a — Enclear Therapies, INC.
- Study coordinator: Glicksman, Marcie a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.